REGENXBIO's Participation in the Genetic Medicines Conference
REGENXBIO Inc. (NASDAQ: RGNX), a leading company in gene therapy, is gearing up to take part in Chardan's 8th Annual Genetic Medicines Conference. This event provides an exciting platform for the company to highlight its novel approaches and progress in genetic treatment methods.
Conference Overview
The conference will take place on a Monday and will feature a fireside chat beginning at 8:30 a.m. ET. During this discussion, industry leaders will share insights on key trends and developments in the realm of genetic medicines. The gathering aims to connect experts, investors, and the wider community to foster the exchange of ideas within the fast-moving field of gene therapy.
REGENXBIO's Dedication to Innovation
Since its founding in 2009, REGENXBIO has made significant advancements in gene therapy with the development of AAV Therapeutics, which represent a revolutionary class of treatments. Their ongoing research focuses on retinal and rare diseases. For example, ABBV-RGX-314 targets wet AMD and diabetic retinopathy, produced in collaboration with AbbVie. Their ambitious development pipeline also includes RGX-202, which is aimed at treating Duchenne muscular dystrophy, and RGX-121 for MPS II.
The Importance of AAV Therapeutics
AAV Therapeutics aim to provide long-lasting solutions for patients, potentially serving as one-time treatments that could significantly alter healthcare delivery. This platform has already had a positive impact on many patients, highlighted by notable successes like Novartis’ ZOLGENSMA, which treats spinal muscular atrophy in children.
How to Join the Conference
If you're interested in following the updates from the conference, a live webcast of the fireside chat will be accessible through the Investors section of REGENXBIO's website. An archived version will also be available online for those who can’t catch the event live.
About REGENXBIO Inc.
REGENXBIO is committed to harnessing the curative potential of gene therapy to change the lives of patients. Their innovative contributions in AAV Therapeutics consistently place them at the leading edge of biotechnology, making vital strides in the treatment of various severe health conditions. As new breakthroughs occur, REGENXBIO remains focused on enhancing healthcare outcomes for individuals around the globe.
Frequently Asked Questions
What does REGENXBIO specialize in?
REGENXBIO focuses on developing AAV Therapeutics for genetic diseases and retinal disorders.
When is Chardan's Annual Genetic Medicines Conference held?
The conference is on a Monday, kicking off with a fireside chat at 8:30 a.m. ET.
How does REGENXBIO impact gene therapy?
The company leads in creating innovative gene therapies that aim to offer lasting solutions for genetic disorders, often collaborating with other pharmaceutical companies.
Where can I view the conference online?
You can watch a live webcast of the conference on REGENXBIO's official website.
What key products has REGENXBIO developed?
REGENXBIO is advancing several programs, including ABBV-RGX-314 for retinal conditions, as well as treatments aimed at Duchenne muscular dystrophy and MPS II.